04:10 PM EST, 11/19/2025 (MT Newswires) -- Jack W Callicutt, Chief Financial Officer, on November 17, 2025, sold 77,920 shares in Galectin Therapeutics ( GALT ) for $478,849. Following the Form 4 filing with the SEC, Callicutt has control over a total of 7,614 common shares of the company, with 7,614 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/xslF345X05/form4.xml